Figure 2 | British Journal of Cancer

Figure 2

From: Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

Figure 2

Brain metastasis outcomes of 77 HER2-overexpressing breast cancer patients with CNS metastasis. (A) Time to brain metastasis (TTBM) from metastasis; Solid (upper) line represents TTBM of 42 patients with CNS metastasis in the post-trastuzumab period. Median TTMB was 15.0 months (95% CI 12.5–17.5). Dotted (lower) line represents TTMB of 35 patients with CNS metastasis in the pre-trastuzumab period. Median TTMB was 10 months (95% CI 6.1–13.9) (P=0.035 by log-rank test). (B) Time to death (TTD) from brain metastasis; Solid (upper) line represents TTD of 42 patients with CNS metastasis in post-trastuzumab period. Median TTMB was 14.9 months (95% CI 11.6–18.2). Dotted (lower) line represents TTMB of 35 patients with CNS metastasis in pre-trastuzumab period. Median TTMB was 4.0 months (95% CI 2.1–5.9) (P=0.0005 by log-rank test).

Back to article page